[HTML][HTML] Strategies of radioiodine ablation in patients with low-risk thyroid cancer
…, I Borget, D Deandreis, S Zerdoud… - … England Journal of …, 2012 - Mass Medical Soc
Background It is not clear whether the administration of radioiodine provides any benefit to
patients with low-risk thyroid cancer after a complete surgical resection. The administration of …
patients with low-risk thyroid cancer after a complete surgical resection. The administration of …
[HTML][HTML] Thyroidectomy without radioiodine in patients with low-risk thyroid cancer
…, C Bournaud, CN Chougnet, S Zerdoud… - … England Journal of …, 2022 - Mass Medical Soc
Background In patients with low-risk differentiated thyroid cancer undergoing thyroidectomy,
the postoperative administration of radioiodine (iodine-131) is controversial in the absence …
the postoperative administration of radioiodine (iodine-131) is controversial in the absence …
The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective …
…, A Buenerd, I Orliaguet, E Mery, S Zerdoud… - Annals of surgical …, 2013 - Springer
Background Sentinel lymph node (SLN) biopsy may improve nodal staging in cervical cancer.
The aims of this study are to determine the rate of unusual patterns of cervical lymphatic …
The aims of this study are to determine the rate of unusual patterns of cervical lymphatic …
Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial
…, B Catargi, D Deandreis, S Zerdoud… - The Lancet Diabetes & …, 2018 - thelancet.com
Background In ESTIMABL1, a randomised phase 3 trial of radioactive iodine ( 131 I)
administration after complete surgical resection in patients with low-risk thyroid cancer, 92% of …
administration after complete surgical resection in patients with low-risk thyroid cancer, 92% of …
Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview
…, M Attard, C Do Cao, S Zerdoud… - Endocrine-Related …, 2021 - erc.bioscientifica.com
Anaplastic thyroid cancer (ATC) is a rare lethal disease. Lenvatinib is an off-label therapeutic
option for ATC in most countries, except in Japan. The aim of this multicenter retrospective …
option for ATC in most countries, except in Japan. The aim of this multicenter retrospective …
[PDF][PDF] Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III …
…, B Catargi, D Deandreis, S Zerdoud… - Journal of Clinical …, 2015 - iris.unito.it
Purpose In the ESTIMABL phase III trial, the thyroid ablation rate was equivalent for the two
thyroidstimulating hormone (TSH) stimulation methods (thyroid hormone withdrawal [THW] …
thyroidstimulating hormone (TSH) stimulation methods (thyroid hormone withdrawal [THW] …
Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine …
S Zerdoud, AL Giraudet, S Leboulleux… - Annales D' …, 2017 - europepmc.org
… Zerdoud S,… Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B,
Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C …
Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C …
MERAIODE: a redifferentiation phase II trial with trametinib and dabrafenib followed by radioactive iodine administration for metastatic radioactive iodine refractory …
S Leboulleux, CD Cao, S Zerdoud… - Journal of the …, 2021 - academic.oup.com
Background: Two-thirds of patients with metastatic differentiated thyroid cancer (DTC) become
refractory to radioactive iodine (RAIR). The inhibition of the MAP-kinase pathway that is …
refractory to radioactive iodine (RAIR). The inhibition of the MAP-kinase pathway that is …
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid …
S Leboulleux, C Do Cao, S Zerdoud, M Attard… - Clinical Cancer …, 2023 - AACR
Purpose: To evaluate the efficacy and safety of dabrafenib-trametinib- 131 I for the treatment
of radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) with a BRAF p.…
of radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) with a BRAF p.…
Factors associated with survival in anaplastic thyroid carcinoma: A multicenter study from the ENDOCAN-TUTHYREF network
…, M Batisse Lignier, L Groussin, M Klein, S Zerdoud… - Thyroid, 2023 - liebertpub.com
Background: Anaplastic thyroid carcinoma (ATC) is a rare and frequently fatal type of thyroid
cancer. The degree of heterogeneity in survival rates for ATC is incompletely studied. This …
cancer. The degree of heterogeneity in survival rates for ATC is incompletely studied. This …